Cookies on the BTG website

We use cookies to ensure that we give you the best experience on our website.

If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the BTG website.

Find out more


Email to a friend
Email to a friend

* Required

Partnered Programmes

In addition to our internal development programmes, we have a number of assets, listed below, in development with our partners.

Partnered Programme Partner Target Indication Status
Abiraterone acetate

Janssen Pharmaceutical Companies of Johnson & Johnson

Breast cancer

Phase II

Our approved products
our critical care

We sell our approved Specialty Pharmaceutical, Interventional Oncology and Interventional Vascular products in the US through our dedicated sales teams and through distributors in other territories.

Developing medicines for the future
developing medicines

At BTG we’re investing in our development programmes in the hope of offering patients new treatment options in the future.